NTLA Stock Analysis: Buy, Sell, or Hold?
NTLA - Intellia Therapeutics, Inc
$11.74
-0.63 (-5.10%)
▼
5d:
-10.46%
30d:
-14.81%
90d:
+24.35%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
NTLA is down 5.0% this week, but smart money is accumulating calls. Top strike: $15 2026-05-15 with 133 OI. Call ratio: 94% View Scanner →
Strength: 6.9/10
Get Alerted When NTLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NTLA is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NTLA is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NTLA is currently trading at $11.74, which is considered oversold relative to its 30-day fair value range of $12.66 to $13.92.
Technical Outlook: Technically, NTLA is in a strong uptrend. The price is currently testing key support at $11.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $25.29 (+104.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NTLA is in a strong uptrend. The price is currently testing key support at $11.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $25.29 (+104.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$12.66 -
$13.92
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding NTLA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 104.4% below Wall St target ($25.29)
- WARNING: Recommendation downgraded due to -10.5% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$12.66 -
$13.92
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$11.75
Resistance Level
$14.02
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.23
Wall Street Target
$25.29
(+104.4%)
Revenue Growth (YoY)
78.8%
Share & Embed Analysis
Last updated: March 30, 2026 1:28 PM ET
Data refreshes hourly during market hours. Next update: 2:28 PM
Data refreshes hourly during market hours. Next update: 2:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Birgit C Schultes
SELL
8508 shares
2026-01-05
James Basta
SELL
10397 shares
2026-01-05
John M Leonard
SELL
34146 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 47 HOLD |
Advanced NTLA Option Strategies
Professional options setups generated by AI based on today's NTLA price and gamma walls.
